Literature DB >> 19552940

Ovarian carcinoma pathology and genetics: recent advances.

C Blake Gilks1, Jaime Prat.   

Abstract

In this review we summarize recent advances in the histopathological diagnostic criteria and molecular pathology of the main subtypes of ovarian surface epithelial carcinoma. These advances have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management. With progress toward subtype-specific treatment of ovarian carcinoma, accurate, reproducible histopathological diagnosis of these subtypes by practicing pathologists is increasingly important.

Entities:  

Mesh:

Year:  2009        PMID: 19552940     DOI: 10.1016/j.humpath.2009.04.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  84 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance.

Authors:  Mingqiu Hu; Xin Fu; Yanfen Cui; Shilei Xu; Yue Xu; Qiuping Dong; Lu Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 3.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

5.  Preliminary observations and clinical value of N-acetyl resonances in ovarian tumours using in-vivo proton MR spectroscopy at 3T.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2011-08-05       Impact factor: 5.315

Review 6.  Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.

Authors:  Guoyan Liu; Da Yang; Yan Sun; Ilya Shmulevich; Fengxia Xue; Anil K Sood; Wei Zhang
Journal:  Pharmacogenomics       Date:  2012-10       Impact factor: 2.533

Review 7.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

8.  Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.

Authors:  James Yarmolinsky; Caroline J Bull; Emma E Vincent; Jamie Robinson; Axel Walther; George Davey Smith; Sarah J Lewis; Caroline L Relton; Richard M Martin
Journal:  JAMA       Date:  2020-02-18       Impact factor: 56.272

9.  Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.

Authors:  Sue V Petzel; Rachel Isaksson Vogel; Tracy Bensend; Anna Leininger; Peter A Argenta; Melissa A Geller
Journal:  J Genet Couns       Date:  2013-05-16       Impact factor: 2.537

10.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.